PFO
BNGO icon

Pathstone Family Office’s Bionano Genomics BNGO Stock Holding History

Pathstone Family Office’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-83
Closed -$30.5K – 1664
2023
Q2 		$30.5K Hold
83
– – ﹤0.01% 1224
2023
Q1 		$55.5K Sell
83
-84
-50% -$74.6K ﹤0.01% 1159
2022
Q4 		$146K Hold
167
– – ﹤0.01% 1414
2022
Q3 		$184K Buy
167
+84
+101% +$111K ﹤0.01% 1363
2022
Q2 		$69K Buy
+83
New +$85.4K ﹤0.01% 1007

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pathstone Family Office's BNGO Position: Q3 2023 in Review

Pathstone Family Office sold out of Bionano Genomics (BNGO) in Q3 2023, closing a stake of 83 shares — an estimated $30.5K sold.

Pathstone Family Office first reported a position in BNGO in Q2 2022 and held it in 5 quarters. The position peaked at $184K in Q3 2022. 46 funds tracked by Wall St. Rank hold BNGO as of Q3 2023.

  • Pathstone Family Office reported no remaining Bionano Genomics position as of Q3 2023 after selling out during the quarter.
  • Pathstone Family Office sold 83 Bionano Genomics shares in Q3 2023, an estimated $30.5K.
  • Pathstone Family Office first reported a position in Bionano Genomics in Q2 2022 and held it in 5 quarters.
  • Pathstone Family Office's Bionano Genomics position peaked at $184K in Q3 2022.
  • 46 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.